STLN Stock — Starling Oncology, Inc.

Starling Oncology, Inc. (STLN)

Updated October 16, 2026.

STLN is a Stock. Total return is -33.7% over the past 6.4 years, 201.7 points behind SPY at 168.0%.

Starling Oncology is an oncology services company operating through specialty pharmacy, patient services, and clinical trials segments. It provides physician services, in-house infusion and specialty pharmacy dispensing, clinical trials management, radiation therapy, and patient support services to cancer patients across the United States. The company does not currently have an established distribution schedule.

STLN performance versus SPY

Price and return data through 2026-10-16.

Total return is -33.7% over the past 6.4 years, 201.7 points behind SPY at 168.0%. Over the past year its total return — price change plus distributions reinvested — is 69.7%. Its deepest 1-year drawdown was 49.8%.

STLN key facts

Asset type

Stock

Asset class

Equity

Inception date

06/04/2020

Distribution frequency

None

Last close

$6.43 (as of 2026-10-16)

Market cap

$655,320,619

Average volume

1773436.0

Beta

0.42

Payout ratio

0.0%

EPS

$-0.29

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

STLN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 49.8%.

Who may consider STLN — and who may not

It is a weaker fit for investors who need monthly cash flow (STLN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on STLN

• All tickers starting with S

Frequently asked questions